Resources

1 Resources for

tesamorelin

  • Subscribe to this listing via:
  • RSS
  • Email

BNET Resources

EMD Serono Snags US license for Tesamorelin From Theratechnologies
Eben Tessari submits:  Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...
Tags: Commercialization, Serono S.A., HIV Virus, Seeking Alpha, Tesamorelin, Eben Tessari, Theratechnologies, Service Management, Healthcare
External links 2008-10-31

Additional Resources

Theratechnologies Learns from the FDA that its Tesamorelin Clinical Program is Moving in the Right Direction.
MONTREAL, QUEBEC, Sep 11, 2007 CCNMatthews via COMTEX -- Theratechnologies (TSX:TH) announced today that it has learned from the US Food and Drug Administration FDA that, based on the information known today, the tesamorelin (TH9507) clinical dev MONTREAL, QUEBEC, Sep 11, 2007 CCNMatthews via COMTEX --...
Tags: FDA
Research articles 2007-09-11
Theratechnologies Learns from the FDA that its Tesamorelin Clinical Program is Moving in the Right Direction
Theratechnologies (TSX: TH) announced today that it has learned from the US Food and Drug Administration FDA that, based on the information known today, the tesamorelin (TH9507) clinical development program is moving in the right direction.
Tags: FDA
Research articles 2007-09-11
Theratechnologies: Movin' On Up
Theratechnologies (THTCF.PK) announced this week that the 52 week data from its confirmatory Phase III trial of its obesity fighting drug, Tesamorelin, showed that the drug was safe and effective. The data also matched up with 52 week data from its first Phase III trial. The data blew away...
Tags: Biotech, Rusty Leonard
External links 2008-12-18
Theratechnologies lands $10M milestone
The FDA has accepted Theratechnologies#039s NDA for tesamorelin, a treatment of excess abdominal fat in HIV patients with lipodystrophy. The acceptance triggers a $10 million milestone payment from partner EMD Serono as part of their collaboration agreement. Release
Tags: treatment, FDA, HIV Virus, milestone payment, Serono S.A.
News items 2009-08-13
  • << Previous
  • page 1 of 1
  • Next >>
advertisement